Expression of the sodium iodide symporter (hNIS) has been detected in breast cancer tissue, but frequently, not at the levels necessary to mediate 131 I accumulation. Transducing the hNIS gene into breast cancer cells with adenovirus could be a tractable strategy to render breast cancer susceptible to radioiodide therapy. We constructed the replication-incompetent virus, AdSERE, in which an estrogen-responsive promoter directs the expression of hNIS. In vitro, we demonstrate that AdSERE mediates hNIS expression and iodide uptake in ER þ breast cancer cells. In vivo, we show that AdSERE-infected ER þ tumors can be imaged due to tracer accumulation; in addition, AdSERE in combination with therapeutic doses of 131 I suppresses tumor growth.
Introduction
Breast cancer is the most common form of female cancer and comprises 18% of all malignancies in women in the Western world. 1 Although screening programs that allow earlier detection of the disease and the use of antiestrogen therapies have increased the rate of survival of breast cancer patients, the fact that most initially responsive tumors develop resistance to all forms of anti-hormonal therapy, 2 with subsequent disease progression and spread, demonstrates that alternative, more effective ways of treatment need to be developed.
Estrogen is an important factor in breast carcinogenesis. Epidemiological data 3 relate breast cancer risk factors to an increased exposure to estrogenic compounds, both those produced systemically and those found in the environment, such as nonylphenol and bisphenol A among others. Estrogens exert their effects on cells through estrogen receptors (ER). The nuclear ER acts as a transcription factor, working with coregulatory factors to activate the transcription of genes whose products are involved in cell proliferation and disease progression. At the time of diagnosis, 60% of breast cancer cases are ER þ .
An attractive strategy to target breast cancer tumors would be to use the activated ER in breast cancer cells to direct the expression of a therapeutic gene, such as the human sodium/iodide symporter (hNIS).
The human sodium/iodide symporter is the protein responsible for the active co-transport of two sodium (Na þ ) cations and one iodide (IÀ) anion across the basolateral membrane of thyroid follicular cells. Previous reports have shown that the ectopic expression of hNIS can be used in combination with tracers, such as 99m Tc 123 I or 124 I, for imaging [4] [5] [6] or with radioisotopes, such as 131 I or 188 Re, for therapeutic purposes. 7, 8 The human sodium/iodide symporter expression has been detected in breast cancer tissues, using immunohistochemistry 9 and high-density tissue microarrays; 10 however, not all hNIS-positive breast tumors are able to accumulate 131 I, as shown by Wapnir et al.
11
in a dosimetry study. Administration of aTRA can enhance hNIS expression and iodide accumulation in breast cancer mouse models, but a potential problem is the fact that to achieve these levels a large dose of aTRA is needed. 12 Transduction of hNIS into breast cancer cells could be a good alternative to overcome these difficulties.
Here, we propose the construction of a replicationdeficient adenovirus, where an estrogen-responsive promoter directs the expression of hNIS to target ER þ breast cancer cells.
Results
Promoter expression in a panel of ER þ and ERÀ cell lines A panel of cell lines, including the ER-positive MCF7 and ZR 75-1 lines, and the ER-negative MDA-MB-468, SKBr3 and A549 lines, was transfected with p4ERE or the empty backbone pGL3-promoter and treated with 10 nM estradiol (E2) or its vehicle, ethanol (EtOH) 1:1000. The promoter activity was determined at 48 h posttreatment by luciferase assay. For comparison, the results were normalized to transfection efficiency determined by the b-gal assay (Figure 1 ).
For ERÀ cell lines, the luciferase activity driven from p4ERE was similar to that from pGL3-promoter meaning that the addition of estrogen responsive elements (EREs) did not have any effect on the activity of the SV40 minimal promoter. The addition of estradiol to the medium did not increase gene expression from p4ERE, as expected for a cell line where ER is not present.
For ER þ cell lines, expression levels from p4ERE in the absence of estradiol were similar to those obtained from pGL3-promoter; however, in the presence of estradiol, the luciferase activity was significantly higher than in cells transfected with p4ERE and ethanol-treated (70-fold for MCF7 and 7-fold for ZR 75-1) or transfected with pGL3-promoter, treated either with estradiol or its vehicle ethanol.
Expression of hNIS after AdSERE-infection
The promoter from p4ERE was cloned upstream of the hNIS gene in the pShuttle vector (Qbiogene, Irvine, CA, USA) and then recombined with AdEasy1 (Qbiogene) to create the adenovirus AdSERE. The structure of this virus and that of the control virus, AdCMV-hNIS, where Figure 1 Activity of the 4ERE promoter in a panel of ER þ and ERÀ cancer cell lines. The cells were transfected with p4ERE or pGL3-promoter (backbone) and cultured in the presence or absence of 10 nM E2; the luciferase activity was detected at 48 h posttransfection. The asterisks indicate statistically significant difference between treatments. the CMV promoter directs the expression of hNIS, are shown in Figure 2 .
ZR 75-1 and SKBR3 cells were infected with AdSERE, AdLacZ or AdCMV-hNIS at an multiplicity of infection (MOI) of 10 PFU per cell, and then cultured in the presence of 10 nM E2 or its vehicle ethanol 1:1000. At an MOI of 10, 60% of the ZR 75-1 cells and 80% of SKBR3 cells are infected, as determined by AdGFP infection (data not shown).
At 24 h after addition of hormones, the cells were fixed and labelled with anti-hNIS. As shown in Figure 3 , only the AdCMV-hNIS-infected cells and the AdSERE-infected estradiol-treated ZR 75-1 cells were immunoreactive for the hNIS protein.
Iodide uptake after infection with AdSERE and AdCMV-hNIS The ER þ MCF7 and ZR 75-1 cells, and the ERÀ MDA-MB-435 and SKBR3 cells were infected with AdSERE at an MOI of 10 PFU per cell and then cultured in the presence of 10 nM E2 or its vehicle ethanol 1:1000. Iodide uptake assays were performed at 24 and 48 h post-addition of hormones (Figures 4a and b) . Estradioltreated AdSERE-infected ER þ cells accumulated radioiodide over the baseline at 24 and 48 h post-addition of hormones, and the amount of accumulated radioiodide was significantly greater from the amount accumulated by ethanol-treated AdSERE-infected cells at those two time points. Iodide uptake was completely inhibited by coincubation with sodium perchlorate.
We did not detect radioiodide accumulation in AdSERE-infected ERÀ cells under any treatment. On these cell lines, membrane-associated hNIS can be demonstrated by infecting them with AdCMV-hNIS, an adenovirus that has a copy of hNIS under the control of the CMV promoter at an MOI of 10 PFU per cell, and then culturing them in the presence of 10 nM E2 or its vehicle, ethanol at 1:1000. Iodide uptake assays were performed at 24 h post-addition of hormones ( Figure 4c ). All four cell lines tested could accumulate radioiodide above the baseline upon AdCMV-hNIS infection. Interestingly, AdCMV-hNIS-infected SKBR3 cells were able to accumulate radioiodide, in contrast to AdSEREinfected SKBR3 cells. Altogether, these data would suggest that radioiodide accumulation would preferentially occur in ER þ , E2-treated cells upon AdSERE infection.
In vivo imaging of AdSERE-treated tumors ZR 75-1 xenografts were grown in female Balb/c nude mice as described in Materials and methods. A group of animals each received an intratumoral injection of AdSERE (10 9 PFU) and another group was left untreated. At 48 h post-injection, the mice were anesthetized and then received an intraperitoneal dose of 18.5 MBq of 99m Tc. Whole-body scans were performed using a SPECT-CT camera for small animals (BIOSCAN). Selected transverse sections of the scans are shown in Figure 5 .
The images obtained by SPECT have a color spectrum, where blue corresponds to a weak signal and red corresponds to a strong signal. In a control mouse (Figure 5a ), signals localized to the thyroid gland, salivary glands, stomach and bladder could be observed. The first three are the sites where endogenous expression of hNIS has been reported previously. 13 The signal in the bladder was due to tracer excretion. The strongest signal was detected in the thyroid gland. No signal was detected in the tumor grown subcutaneously on the left flank of the animal.
A strong signal at the level of the left flank was detected in test animals (an example is shown in Figure 5b ), at the site where the tumor was grafted. Sodium/iodide symporter gene expression for estrogen-regulated imaging CA Montiel-Equihua et al
The tumors from the scanned animals were collected immediately after imaging, then formalin-fixed, paraffinembedded and subjected to hNIS immunohistochemistry.
As observed in Figure 6 , only the AdSERE-treated tumors (showed immunoreactivity for hNIS. As expected, the symporter was localized on the membrane of the cells.
In vivo therapeutic effect of AdSERE in combination with 131 I Tumors were grown in Balb/c nude mice and treated as described in Materials and methods. As shown in Figure 7 , the tumors in the animals that received AdSERE alone continued to grow until the end of the experiment. The tumors in the animals that received an intraperitoneal injection of 131 I alone maintained the same size for 3 days, but continued to grow afterwards.
In contrast, the tumors in the animals that received injections of both AdSERE intratumorally and 131 I intraperitoneally showed a slight reduction on day 10 and then maintained the same size for the rest of the experiment.
No changes in behavior, weight or any sign of health problem due to the treatment were observed in any of the animals throughout the experiment.
Livers of the animals subjected to this experiment were recovered on day 20 and subjected to hematoxylin-eosin staining, as shown in Figure 8 .
Liver sections from the AdSERE-and 131 I-treated animals showed that no necrotic areas were detected in any of the samples. There were no morphological features indicating viral infection in the livers of the animals Figure 6 Immunohistochemistry for hNIS. The tumors from the AdSERE-injected and non-treated mice were obtained immediately after scanning, paraffin-embedded, fixed and subjected to IHC staining for hNIS. We observed foci of hNIS-positive cells on the AdSERE-treated tissue. treated with AdSERE or AdSERE þ 131 I. However, there were minor degrees of hepatic steatosis (fatty deposition) in some of the animals treated with both virus and radioiodine (Figure 8 ).
Discussion
The use of endocrine therapy, mainly tamoxifen, is one of the key factors in the decline in mortality rates for breast cancer patients. At the time of diagnosis, about 60% of all breast cancer cases are ER þ , but only 40-70% of them respond to endocrine therapy. 1, 14 Loss of ER expression has been demonstrated only in approximately 20% of patients with acquired tamoxifen resistance. 15, 16 Based on this evidence, we proposed the design of an alternative mode of therapy that would take advantage of the prevalence of ER in breast cancer tumors.
Radioiodine therapy, already applied for thyroid cancer, is regarded as an option for breast cancer therapeutics due to the fact that expression of hNIS has been detected in 80% of breast cancer cases; 9,10 however, the proportion of hNIS-positive cases that are able to take up radioiodide to the levels required for imaging and/or therapy is only 25%. 11 If radioiodide therapy is to be applied for breast cancer, it is necessary to increase the expression of hNIS in tumor cells.
Kogai's group has explored the possibility of increasing the levels of endogenous hNIS expression with aTRAtreatment; however, the dose required for therapeutic levels is high and the long-term administration of aTRA leads to a decrease in hNIS expression due to RARa downregulation. 12 A possible solution for this problem could be the combination of retinoic acid with other drugs like dexamethasone 17 to enhance mammary gland hNIS expression, or the transduction of hNIS into tumor cells using viruses. Dwyer and colleagues have proposed the use of the MUC1 promoter to regulate the expression of hNIS in tumor cells. 7 In this study, we have investigated the potential of an ER-responsive promoter (4ERE), to drive the expression of hNIS in ER þ breast cancer cells.
First, we confirmed the estrogen receptor-dependent activation of the promoter 4ERE, which was capable of activating luciferase expression preferentially in ER þ , estradiol-treated cells. We proceeded to construct the adenovirus, AdSERE, placing the 4ERE promoter upstream of hNIS. The recombinant cassette was flanked with two copies of the HS4 chicken globin insulator, as the need to isolate tissue-specific promoters from viral enhancers to preserve specificity has previously been reported. 18 In ER þ estradiol-treated cells infected with AdSERE, the transporter was expressed and localized mainly at the cytoplasmic membrane, whereas there was no detectable hNIS expression in ERÀ AdSERE-infected cells. In addition to the typical membrane localization of hNIS, we observed some intracellular immunoreactivity, particularly in AdCMV-hNIS-infected cells. Previous reports indicate such localization is not an unusual finding in breast cancer cells; 9 however, only the hNIS that localizes to the cytoplasmic membrane is able to transport iodide. To prove the transporter transduced by AdSERE was functional, we performed iodide uptake assays and observed that only ER þ estradiol-treated cells were capable of accumulating radioiodide after infection with AdSERE.
Most ectopically expressing hNIS cells can take up radioiodide. However, a possible explanation for the absence of radioiodide uptake in AdSERE-infected ERÀ cells would be the expression of a non-functional hNIS. Upon infection with the non-selective virus, AdCMVhNIS, both ER þ and ERÀ cells were able to express the transporter and take up radioiodide, confirming that the lack of radioiodide uptake in AdSERE-infected ERÀ cells was not due to defects in the expression of hNIS or its incorrect subcellular localization.
All together, our data suggest that the selected promoter is capable of directing ER-dependent estradioldependent hNIS expression in AdSERE-infected cells.
We then developed a xenograft model using ZR 75-1 cells, in which we tested the ability of AdSERE to transduce hNIS after intratumoral injection. By single positron emission tomography, we observed that at 48 h post-injection of virus AdSERE, tumors were capable of accumulating the radiotracer, whereas untreated tumors did not.
In a subsequent experiment, we observed that 131 I administration after AdSERE intratumoral injection resulted in tumor stasis, and this effect did not occur when either the radioisotope or the virus were administered on their own.
We recovered the livers from the mice to look for signs of cytotoxicity, caused either by the administration of radioiodide or virus. None of the samples from animals treated with 131 I or from animals treated with virus alone showed signs of abnormality, but some of the sections from the AdSERE þ 131 I-treated animals showed swollen cells with signs of fatty degeneration. Fatty degeneration of the liver is most frequent due to nutritional and metabolic causes and it is not usually associated with viral infection. Systemic administration of radioiodine has not been associated with liver damage, therefore we consider these observations are not associated with the treatment, although this would require a formal toxicological study if the therapy was to be advanced to regulatory approval for application in the clinic.
It has been previously suggested that the mere presence of hNIS in extrathyroidal tissues would not be enough to produce a therapeutic effect after radioiodide administration, since these tissues are not capable of organifying iodide and, therefore, the half life of the radioisotope at the target site is short. 19 However, we did observe a suppression of tumor growth in the animals that received a combination of AdSERE and 131 I; therefore, the lack of organification in breast cancer cells seems not to pose an obstacle for the use of radioiodide as a therapeutic tool. These results are in agreement with previously published data. 7 Hence, AdSERE in combination with 131 I was capable of producing a therapeutic effect without being significantly toxic. Nevertheless, some additional considerations could be used to improve the therapeutic efficacy of the combinatorial treatment. A regime including multiple injections of adenovirus/radioiodine is likely to enhance tumor reduction. Using a conditionally replicating adenovirus as a platform to deliver hNIS could also be a good alternative; such a virus would be able to replicate and spread within the tumor, thus increasing the rate of tumor-cell clearance in combination with radioiodide uptake.
In addition, the use of other radioisotopes with higher energy emissions, also transported by hNIS, could potentially boost the efficacy of the regime. Both 188 Re and 211 At have been shown to deliver approximately five times the dose of radiation delivered by 131 I to hNISexpressing tumors. 20, 21 In conclusion, the transduction of hNIS in breast cancer cells using adenovirus could help to overcome the difficulties encountered for the use of radioiodide therapy in this type of cancer.
Materials and methods

Cells and plasmids
All the cell lines and media were obtained from the Cell Services Department, Cancer Research, UK.
Human embryonic kidney 293 cells, the lung cancer cell line, A549, the breast cancer cell lines, MCF7, MDA-MB-231 and MDA-MB-435, were maintained in DMEM 10% fetal calf serum and 10% CO 2 . The breast cancer cell lines, SKBR3 and ZR 75-1, were maintained in RPMI 10% fetal calf serum and 5% CO 2 . Fetal calf serum and estradiol were purchased from Sigma, Dorset, UK.
Studies with estradiol, used at a final concentration of 10 nM, were performed in phenol red-free medium supplemented with double charcoal-stripped serum (DCSS, First Link, Birmingham, UK).
The plasmid pGL3-4EREc38-luciferase (referred here as p4ERE) was a kind gift from Dr C Klinge (University of Louisville). The estrogen-responsive promoter in p4ERE is an artificial promoter constructed by inserting four EREs in the multicloning site of the pGL3-promoter vector (Promega, Southampton, UK) and it has been used previously as a reporter vector for ER activity. 22 
Viruses
To construct the adenovirus AdSERE, a copy of the chicken globin insulator double-core was cloned in the KpnI site of pShuttle (Qbiogene), to create the plasmid pShuttle-insulator. The fragment containing a copy of the hNIS, a copy of the poly A signal from the bovine growth hormone and a copy of the chicken globin insulator double-core was cloned in the sites NcoI-SalI, downstream of the promoter in the plasmid pGL3-4EREc38-luciferase. The fragment NotI-SalI, containing the promoter, hNIS, polyA signal and chicken globin insulator was excised and cloned downstream of the insulator in the plasmid pShuttle-insulator, creating the plasmid pSERE. pSERE was recombined with AdEasyI (Qbiogene) in electrocompetent BJ5183 bacteria, generating the genome of the virus AdSERE. The virus was packaged and produced as described previously. 23 The replication-incompetent AdCMV-hNIS virus, used here as a positive control, has been described previously. 5 
Transfection
Cells were plated at a density of 100 000 per well in 6-well plates. FuGENE 6 (Roche, West Sussex, UK) was used for all transfections, diluted in serum-free antibiotic-free culture medium in a proportion of 3:1 volume/weight to the DNA. To normalize for transfection efficiency, the cells were co-transfected with the pcDNA 3.1/mycHis(À)/lacZ plasmid (Invitrogen, Paisley, UK). After overnight transfection, the medium was replaced for 10% DCSS phenol red-free medium supplemented with 10 nM estradiol or ethanol, 1:1000 dilution.
Infection
For viral infections, serum in the medium was reduced to 5%. In studies with estradiol, cells were exposed to the viral suspension for 1.5 h prior to addition of the hormone or its vehicle, ethanol.
Luciferase assay
Luciferase activity was determined using the luciferase assay kit from Promega. At 48 h post-transfection, cells were washed once with phosphate buffered saline (PBS) and then lysed with 0.2 ml per well of reporter lysis buffer (RLB, Promega). Aliquots of 20 ml of each lysate were loaded in opaque 96-well plates and read using a luminometer (Luminoskan Ascent). Results were expressed as luciferase units per milliunit of b-gal to normalize for transfection efficiency.
b-galactosidase assay b-galactosidase activity was determined using the b-galactosidase kit from Promega. Aliquots of 50 ml of the lysates obtained for luciferase activity determination were loaded into a 96-well plate, mixed in equal proportion with the assay 2 Â buffer and incubated at 37 1C for 30 min. The reaction was stopped by adding 150 ml of 1 M sodium carbonate solution to each well. The absorbance of the samples at 420 nm was determined in a plate reader (Opsys MR; Dynex). The protein content was determined using the bicinchoninic acid kit (Pierce, Perbio Science, Cramlington, UK). The results were expressed as b-galactosidase milliunits mg À1 protein.
Immunofluorescence Cells were seeded on sterile glass coverslips at a density of 2.5 Â 10 5 cells and incubated overnight at 37 1C. Next day, the cells were infected at MOI 10 with AdSERE, AdCMV-hNIS or AdLacZ for 1 h and then supplemented with 10 nM estradiol or its vehicle, ethanol. After 24 h, the cells were fixed with 3% paraformaldehyde in PBS for 15 min at room temperature and then permeabilized with 0.1% TritonX-100 in PBS for 5 min at 4 1C. A dilution of 1:150 of hNIS Ab1 (FP5a) antibody (Neomarkers, LabVision, Runcorn, UK) was applied to the coverslips for 30 min at room temperature. The cells were stained with a 1:1000 dilution of the secondary goat anti-mouse 546 nm Alexa fluor conjugate antibody (Invitrogen) in 5% heat-inactivated goat serum in PBS for 30 min at room temperature in the dark. The nuclei were stained with DAPI diluted 1:500 in PBS for 5 min. The coverslips were mounted on glass slides with a drop of permafluor mounting medium. The slides were left to dry overnight at room temperature in the dark, and then stored at 4 1C.
Images were captured using a Zeiss laser-scanning confocal microscope LSM 510.
Iodide uptake Cells were seeded in 24-well plates at 100 000 cells per well, and infected with adenovirus as described above. Each well was exposed to 0.5 ml of Hank's buffered saline solution (HBSS, GIBCO-Invitrogen) supplemented with 7.4 kBq ml À1 of ( 125 I)NaI (specific activity of 740 MBq mmol
À1
, Amersham, Little Chalfont, UK). Some wells were supplemented with Na ClO 4 to a final concentration of 100 mM to inhibit hNIS-mediated iodide influx. Plates were incubated 1 h at 37 1C, washed with cold PBS and lysed with 0.5 ml of Lysis buffer. An aliquot of 0.4 ml from the lysate was diluted in 3.6 ml of scintillation liquid (Amersham) and analyzed using the Multi-purpose scintillation counter LS 6500 (Beckman Coulter, High Wycombe, UK). The protein concentration was determined using the bicinchoninic acid kit (Pierce, Perbio Science). The results were expressed as a percentage of the scintillation counts obtained from 0.4 ml of Na-125 Isupplemented medium, normalized to the protein content.
ZR 75-1 xenografts Female Balb/c nu/nu mice of 6-8 weeks of age (Harlan Iberica) were anesthetized using an intraperitoneal dosis of 1.5 ml kg À1 of ketamine/xylazine in a ratio of 2:1. A small incision was made into the skin, close to the neck, where a 60-day slow-release 17-estradiol (0.72 mg) pellet was implanted (Innovative Research of America, FL, USA). The wound was closed using a metal clip. Twentyfour hours later, 5 Â 10 6 ZR 75-1 cells in PBS were injected in proportion 1:1 with liquefied Matrigel matrix (BD Biosciences, Oxford, UK) in the left flank in the operated animals. All procedures followed UK Home Office regulations for animal experimentation.
SPECT-CT scan
Tumor-bearing animals, obtained as described above, were separated into two groups of six animals; when the tumors reached 0.5 cm 2 . One group received an intratumoral injection of 10 9 PFU AdSERE and the second was left untreated. Forty-eight hours later, both groups received an intraperitoneal dose of 18.5 MBq of 99m Tc. The mice were scanned using a SPECT-CT scanner for small animals (BIOSCAN). A topogram was taken and the limits of the scan were determined. A CT and a SPECT whole-body scan were performed, with a time of 100 s per acquisition. The images were reconstructed with the MEDISO software (Medical Imaging Systems); fusion of SPECT and CT images was carried out using the PMOD software.
Therapeutic effect
Tumors were grown in female Balb/c nude mice as described above except that each animal received inoculation of tumor cells into both flanks. The mice received thyroxine (Sigma) at a concentration of 5 mg l À1 in their drinking water, 3 days prior to treatment. When the tumors reached 0.5 cm 2 , the animals were divided into three groups of three animals each. Two groups received an intratumoral injection of 10 9 PFU AdSERE. Fortyeight hours later, the non-treated group and one of the adenovirus-treated groups received an intraperitoneal dose of 2 mCi ( 131 I)NaI. The length and width of the tumors were measured every two days and the size was calculated using the formula: Tumor area ¼ LW; where L is length and W is width.
Histology
Tumor and liver tissues obtained from the in vivo experiments were formalin-fixed and paraffin-embedded. Sections of 4 mm were obtained from the blocks for hematoxylin-eosin staining and immunohistochemistry. The photographs were taken using an Olympus BX51 microscope and Studio Lite software.
Detection of hNIS was done using the Discovery platform from Ventana Medical Systems Inc. The primary antibody hNIS Ab1 (FP5a) from NeoMarkers, Lab Vision UK was used at a 1:100 dilution. The slides were treated using the MoMap Kit and DABMap kit (Ventana Medical Systems Inc., AZ, USA) as indicated by the manufacturer.
Statistical analysis
Statistical analyses were carried out using the Prism (GraphPad) software and P-values were calculated using the Student's t-test.
